Farmas USA

Apoyo esa idea

PT: 22$

https://stocknews.com/news/exel-goldman-sachs-initiates-as-a-neutral-22pt/

EXEL

SGYP 

Gracias Framus, solo me preocupa que los cortos siguen recios a no bajar posicion y aqui hay dos,o 3 cosas  o bajan este proximo reporte del 15/09/2018 lo que me daria el pistoletazo de salida o se nos viene algo inesperado por ahi como un Merger o algo que no suele gustar de forma temporal para resurgir otra vez.,, o sueltan una good news que con ese ranking de 1 que le da la pagina short squeeze , es lo que podemos espèrar.

MLNT

Esta semana CHMP (el "PDUFA europeo") para Baxdela (treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in adults). Es posible que las news de aprobación o denegación las den la semana que viene, no hay confirmación oficial tan rápido como en USA.

http://www.ema.europa.eu/docs/en_GB/document_library/Agenda/2018/09/WC500255488.pdf

Éstas van sin paracaídas...y yo dentro de las 2 primeras, menos mal que me salí de las otras 2.

ADXS EXEL AKAO RDUS

Inovio develops H3N2 Influenza DNA vaccine

Inovio Pharmaceuticals (NYSEMKT: INO)  announces that its SynCon vaccine approach using a collection of DNA antigens generated broadly protective antibody responses against the most deadly strains of the H3N2 influenza viruses from the past 50 years and provided complete protection against heterologous lethal challenge in a preclinical study.

Study results were published in the journal, Human Gene Therapy, in an article entitled, “A Synthetic Micro-Consensus DNA Vaccine Generates Comprehensive Influenza-A H3N2 Immunity and Protects Mice Against Lethal Challenge by Multiple H3N2 Viruses.” This work was supported by a grant from the U.S. National Institutes of Health.

Inovio is currently in discussions with third-party funders to support further development of the company’s technology with its advantages in promoting global human health.

https://seekingalpha.com/news/3390691-inovio-develops-h3n2-influenza-dna-vaccine?app=1#email_link

Progenics adds AZEDRA to NCCN guidelines for pheochromocytoma and paraganglioma

Sep. 17, 2018 6:47 AM ET|About:  Progenics Pharmaceuticals ... (PGNX)|By:  Mamta Mayani, SA News Editor 

Progenics Pharmaceuticals (NASDAQ: PGNX)  announces that AZEDRA (iobenguane I 131), the Company’s radiotherapeutic, has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors v 3.2018. NCCN Guidelines are widely recognized and used as the standard for clinical policy in oncology by clinicians and payors.

NCCN Guidelines have been updated with AZEDRA, the first and only FDA approved treatment of patients 12 and older with iobenguane scan positive, metastatic pheochromocytoma or paraganglioma. Pheochromocytoma and paraganglioma are rare neuroendocrine cancers that arise from cells in and around the adrenal glands.

https://seekingalpha.com/news/3390597-progenics-adds-azedra-nccn-guidelines-pheochromocytoma-paraganglioma?app=1#email_link

Entré en 1.67 a ver como se mueve esta semana … 

SGYP